SG Power Limited has announced a major strategic transformation aimed at repositioning the company as a healthcare-focused business, with an initial emphasis on pharmaceutical licensing, distribution and trading.
According to a disclosure submitted to the Pakistan Stock Exchange (PSX), the company’s Board of Directors approved the strategic initiative at its meeting held on April 16, 2026. The move is intended to place the company in a sector that the board describes as having strong demand fundamentals and scalable revenue potential.
Proposed Change in Business Scope and Name
As part of the transformation, SG Power Limited plans to amend its Memorandum and Articles of Association to allow the company to operate across pharmaceutical, healthcare and allied sectors.
The company also plans to change its name to reflect its new healthcare-oriented business direction. These amendments are subject to the required corporate and regulatory processes.
Registered Office to Move to Punjab
The board has also approved relocating the company’s registered office from Sindh to Punjab. The company said the relocation is intended to align its legal and administrative base with its operational focus.
Authorized Capital Proposed at Rs800 Million
Another key part of the plan is an increase in the company’s authorized share capital to Rs800 million.
The additional authorized capital is intended to support future capital-raising initiatives and working capital requirements as the company develops its new business operations.
DRAP Licensing Process to Begin
SG Power Limited said it will initiate the process of obtaining the necessary licenses from the Drug Regulatory Authority of Pakistan (DRAP). These licenses will be required for the company to enter the pharmaceutical supply chain.
The licensing process remains subject to completion of the proposed amendments and the necessary approvals from regulators and shareholders.
Focus on Distribution and Strategic Partnerships
The company also intends to establish domestic and international subsidiaries or special purpose vehicles (SPVs). It plans to pursue strategic partnerships, including distribution arrangements and joint ventures with local and international pharmaceutical operators.
The board said a distribution-led entry strategy is expected to allow relatively rapid market entry with comparatively low capital intensity. The strategy is designed to generate revenue in the near term while building a scalable presence within the pharmaceutical ecosystem.
90–120 Day Implementation Target
According to the disclosure, execution of the proposed strategy is targeted within a 90- to 120-day timeframe. The company aims to transition toward an active and revenue-generating healthcare business during this period.
The board said the transformation has the potential to enhance the company’s scale, earnings profile and market positioning, although the actual outcome will depend on successful execution, regulatory approvals and the development of its planned pharmaceutical operations.
Extraordinary General Meeting Planned
To proceed with the proposed changes, the Board of Directors has approved convening an Extraordinary General Meeting (EOGM). Shareholders will be asked to consider and approve the relevant matters in accordance with applicable laws and regulations.
What the Transformation Means
SG Power Limited’s announcement marks a significant proposed change in its business direction, moving from its existing profile toward healthcare and pharmaceutical activities.
The strategy covers several areas, including pharmaceutical licensing, distribution, trading, partnerships, subsidiaries and joint ventures. The company’s immediate focus appears to be establishing a distribution-led presence before potentially expanding its operations across the broader pharmaceutical ecosystem.
The company’s disclosure was issued to the Pakistan Stock Exchange in accordance with Section 96 of the Securities Act, 2015 and Clause 5.6.1(a) of the PSX Rule Book.
